Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

NCT02715882 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: CBLB502
DRUG: Placebo

Sponsor

BioLab 612 LLC

Collaborators

[object Object]